Tasigna nilotinib: Phase III data

The open-label, international Phase III ENESTcmr trial in 207 patients showed that a non-significantly greater proportion of patients who switched to Tasigna achieved a confirmed CMR, the primary endpoint,

Read the full 290 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE